SCHEMBL6683142

SCHEMBL6683142

[O]C(OCC(F)(F)C(F)F)C(F)(F)C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28835803 0.79 HTT (0.34)
SCHEMBL6683147 0.74 KDM4E (0.32)
SCHEMBL20971279 0.73 MEN1 (0.34) MEN1KMT2A
SCHEMBL186811 0.71 MEN1 (0.33) MEN1KMT2A
SCHEMBL9481009 0.70 MEN1 (0.32) MEN1KMT2A
SCHEMBL22117654 0.68 MEN1 (0.30) MEN1KMT2A
SCHEMBL9077347 0.67 MEN1 (0.35) MEN1KMT2A
SCHEMBL23793326 0.67 MAPK1 (0.32) MEN1KMT2A
SCHEMBL5704683 0.67 MEN1 (0.32) MEN1KMT2A
SCHEMBL28891086 0.67 MEN1 (0.32) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040249147-A1 Synthesis of key azole-antifungal intermediates RANBAXY LABORATORIES LIMITED (IN) 2004-12-09 US disclosed
EP-1432704-A1 SYNTHESIS OF KEY AZOLE-ANTIFUNGAL INTERMEDIATES RANBAXY LABORATORIES, LTD. (IN) 2004-06-30 EP disclosed
WO-2003027103-A1 SYNTHESIS OF KEY AZOLE-ANTIFUNGAL INTERMEDIATES RANBAXY LABORATORIES LIMITED (IN) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249147-A1 Synthesis of key azole-antifungal intermediates ERG28, CYP11B1, CYP2E1 MEN1 112/4885KMT2A 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.